Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Government and Public Sector Government 42nd ICAAC 2002 - Biodefense and Emerging Infections
Publications

(Currently 512486 Items)


Partners


Government / REPORT INFORMATION

42nd ICAAC 2002 - Biodefense and Emerging Infections

DateNov, 2002
Pages42
Price / format$1900 / Online Download
$1900 / Hard Copy Mail Delivery
$3800 / Global Site License

$1 900 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
42nd ICAAC 2002 - Biodefense and Emerging Infections

 
The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the world's premier meeting on infectious diseases and antimicrobial agents, organized by the American Society for Microbiology. This Brief discusses some of the keynote lectures at the 42nd ICAAC 2002, focusing on emerging and re-emerging infections and the increasing threat of bioterrorism.The key pathogens and bioterrorism threats are identified. Incentives for developing new products for biodefense are discussed.Emerging and re-emerging infections are profiled. Key commercial opportunities to develop and commercialize relevant products are identified.The bioterrorism-related pharmaceutical market can offer potential benefits for smaller niche players. Whilst the potential for blockbusters is limited, government grants can lead to assured revenues, without the need for extensive detailing activities. In addition, the publicity surrounding platform technologies arising from government purchase of such products can give a major boost to small players at minimal cost.The low incidence of rare and emerging infectious diseases, such as West Nile disease, present market opportunities for prophylactics, if not for novel therapeutics. Given the probable reluctance of government agencies to reimburse prophylactic products in non-risk groups, there is potential to introduce schemes such as co- or full- patient payment.Identify the commercial potential of entering into biodefense and emerging disease niche marketsUnderstand how compulsory licensing could act as a major disincentive to expanding the indication of existing products to meet bioterrorist threats.



Table of contents:

Overview
Introduction
The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is
the world's premier meeting on infectious diseases and antimicrobial agents,
organized by the American Society for Microbiology. This Brief discusses some of
the keynote lectures at the 42nd ICAAC 2002, focusing on emerging and
re-emerging infections and the increasing threat of bioterrorism.
Scope
The key pathogens and bioterrorism threats are identified. Incentives for
developing new products for biodefense are discussed.
Emerging and re-emerging infections are profiled. Key commercial opportunities
to develop and commercialize relevant products are identified.
Report Highlights
The Bioterrorism related pharmaceutical market can offer potential benefits for
smaller niche players. Whilst the potential for blockbusters is limited,
government grants can lead to assured revenues, without the need for extensive
detailing activities. In addition, the publicity surrounding platform
technologies arising from government purchase of such products can give a major
boost to small players at minimal cost.
The low incidence of rare and emerging infectious diseases, such as West Nile
disease, present market opportunities for prophylactics, if not for novel
therapeutics. Given the probable reluctance of government agencies to reimburse
prophylactic products in non-risk groups, there is potential to introduce
schemes such as co- or full- patient payment.
Reasons to Purchase
Identify the commercial potential of entering into biodefense and emerging
disease niche markets
Understand how compulsory licensing could act as a major disincentive to
expanding the indication of existing products to meet bioterrorist threats.
DRIVERS AND TRENDS
The keynote lectures at the 42nd ICAAC 2002 focused on emerging and re-emerging
infections and the increasing threat of bioterrorism.
The events of September 2001 highlighted the fact that Western civilization is
not unassailable, and that the unpredictability of terrorist attacks are a
realistic threat to the lives and economies of target countries. There has,
therefore, been increasing government activity to prepare for the threat of
further such attacks. The market for biodefense is guaranteed but limited. There
are, however, a number of factors that could attract smaller companies to enter
the market. Likewise, the market for emerging infections, such as West Nile
Virus, is highly specific. This brief explores the commercial opportunities to
be found within both markets.
BIOTERRORISM
What is the current market potential for biodefense products? What are the risks
involved in market entrance? This section provides:
An overview of the pathogens that the CDC considers to be the most dangerous
agents that could be used as bioterrorist weapons
The commercial opportunities for companies looking to enter this market are
discussed, alongside the risks involved in the development of biodefense
agents
Anthrax and smallpox are explored in greater detail, as the two agents that
the CDC is currently giving highest priority to, including an assessment of
current and future product pipelines.
EMERGING AND RE-EMERGING INFECTIONS
Emerging and re-emerging diseases can pose a threat to entire populations. The
most recent emerging disease to hit the headlines in the US is West Nile Virus
(WNV). This section of the brief summarizes the epidemiology of the disease, and
current and future product pipelines. The potential strategies to maximize
revenue gained from entering this market are also discussed.
In addition to WNV, the potential threats of a major flu pandemic, and current
strategies that are in place to deal with this eventuality are discussed.
ACTION POINTS
Understand the key themes arising from the 42nd ICAAC conference
Identify the commercial potential of entering into the biodefense market
Pinpoint current economically important emerging infections
DATASETS
Table 1: CDC classification of potential agents of bioterrorism
Table 2: Potential agents of bioterrorist attacks
Table 3: Current anthrax products for treatment and prophylaxis
Table 4: Pipeline products for anthrax treatment and prophylaxis
Table 5: Current smallpox vaccines in development
Table 6: Companies developing West Nile Virus prophylaxis
Table 7: Currently manufactured influenza vaccines
Table 8: Marketed products used for influenza treatment
Figure 1: Influenza Pandemics 1900-2000




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com